Entero Therapeutics, Inc.
ENTO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $8,701 | $4,238 | $13,213 | $38,690 |
| - Cash | $163 | $3,712 | $1,363 | $8,249 |
| + Debt | $141 | $827 | $884 | $1,030 |
| Enterprise Value | $8,678 | $1,353 | $12,734 | $31,472 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$29 | -$106 | -$537 |
| % Margin | – | – | – | – |
| EBITDA | $33 | -$15,743 | -$14,584 | -$57,989 |
| % Margin | – | – | – | – |
| Net Income | -$18,059 | -$15,795 | -$14,630 | -$58,538 |
| % Margin | – | – | – | – |
| EPS Diluted | -5.26 | -46.96 | -407.37 | -27,544.98 |
| % Growth | 88.8% | 88.5% | 98.5% | – |
| Operating Cash Flow | -$9,218 | -$12,378 | -$22,344 | -$32,288 |
| Capital Expenditures | $0 | -$500 | $0 | -$10,319 |
| Free Cash Flow | -$9,218 | -$12,878 | -$22,344 | -$42,608 |